What are the potential benefits of Linaclotide?

First FDA-approved GC-C agonist (2012). Effective for chronic idiopathic constipation and IBS-C. Dual mechanism: fluid secretion + visceral pain reduction. Minimal systemic absorption ensuring GI-localized activity. Pediatric chronic constipation (6-17 years, approved 2017)

What compounds work synergistically with Linaclotide?

Linaclotide has been studied alongside Plecanatide, Fiber supplements, Low FODMAP diet for potential synergistic effects.

Linaclotide — Mechanism, Benefits, Research & Synergies

Overview

Linaclotide (Linzess/Constella) is a 14-amino acid synthetic peptide agonist of guanylate cyclase-C (GC-C) that is structurally derived from the heat-stable enterotoxin (STa) produced by enterotoxigenic Escherichia coli—the cause of traveler's diarrhea. FDA-approved in 2012 for chronic idiopathic constipation and IBS-C, linaclotide works locally in the intestinal epithelium to stimulate fluid secretion and reduce visceral pain sensitivity. It was the first GC-C agonist approved and established the mechanism for this therapeutic class.

Mechanism of Action

Linaclotide activates GC-C receptors on intestinal epithelial luminal surfaces, generating intracellular cGMP that activates CFTR chloride channels and the cGMP/PKG-II pathway, promoting chloride and bicarbonate secretion into the intestinal lumen. This fluid secretion softens stool and accelerates transit. Additionally, cGMP exported to the subepithelial space acts on afferent nociceptive fibers expressing cGMP-sensitive ion channels, reducing visceral pain sensation—the mechanism responsible for linaclotide's IBS-C pain relief beyond its laxative effect.

Potential Benefits

First FDA-approved GC-C agonist (2012)
Effective for chronic idiopathic constipation and IBS-C
Dual mechanism: fluid secretion + visceral pain reduction
Minimal systemic absorption ensuring GI-localized activity
Pediatric chronic constipation (6-17 years, approved 2017)

Research Dosage Notes

The following reflects doses used in published research studies. This is not medical advice.

CIC: 145 mcg orally once daily. IBS-C: 290 mcg orally once daily. Take 30 minutes before first meal of the day.

Amino Acid Sequence

Cys-Cys-Glu-Tyr-Cys-Cys-Asn-Pro-Ala-Cys-Thr-Gly-Cys-Tyr (with three disulfide bonds)

Side Effects & Safety

Diarrhea (dose-dependent, most common adverse effect)
Abdominal pain
Flatulence
Black box warning: avoid in pediatric patients under 6 years

Synergistic Compounds

The following compounds have been studied alongside Linaclotide for potential complementary or synergistic effects:

PlecanatideFiber supplementsLow FODMAP diet

Learn More

Beginner's GuideNew to peptides? Start here Stacking GuideSynergistic combinations Administration RoutesSubQ, IM, oral, nasal & more Reconstitution CalculatorCalculate exact dosing Peptides vs SARMsFull comparison How Peptides Are MadeSPPS, purification & QC

References & Further Reading

[object Object]
[object Object]

Quick Facts

Molecular Weight	1527.7 g/mol
Research Status	FDA-approved 2012 for CIC and IBS-C. Pediatric indication added 2017. Extensive post-marketing safety data.

More Peptides in This Category

BPC-157 TB-500 GHRP-6 Hexarelin GHK-Cu Follistatin-344

Linaclotide